For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and Tafamidis meglumine represents a true change. These innovative therapies protect the transthyretin protein, preventing its harmful build-up and lessening the severity of the disease . Patients are now experiencing benefits